The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) have updated and revised their 2013 evidence-based guideline:
The "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors" continues to set evidence-based standards for clinical molecular testing of non-small cell lung cancers (NSCLC) that effectively guides targeted therapy and treatment.
Philip T. Cagle, MD, on behalf of CAPYasushi Yatabe, MD, PhD, on behalf of IASLCNeal Lindeman, MD on behalf of AMP
This guideline was endorsed by the American Society of Clinical Oncology on February 5, 2018.